Sant Joan d'Alacant | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 3	2026-08-19		NCT05774951
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects	Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 3	2026-08-06		NCT05232916
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 3	2025-11-19		NCT04565054
Integrated Approach in Frail Older People with Atrial Fibrillation	Arrhythmias, Cardiac, Arterial Occlusive Diseases, Chronic Disease, Disease Attributes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atrial fibrillation, brain disorder, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, chronic obstructive pulmonary disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, heart failure, hypertensive disorder, lung disorder, metabolic disease, nervous system disorder, obstructive lung disease, peripheral arterial disease, peripheral vascular disease, respiratory system disorder, stroke disorder, transient ischemic attack, vascular disorder	Recruiting	Not applicable	2025-01-14		NCT06775028